INTRODUCTION {#SEC1}
============

In all living cells, the ribosome nanomachine assisted by tRNAs and translation factors decodes the genetic information contained within messenger RNAs (mRNAs) to synthesize the corresponding proteins. mRNA translation is a highly complex process which in addition to the numerous factors involved, requires RNA and protein maturation events for faithful and timely protein production. Among those events, post-transcriptional modifications are found on all components and in the three domains of life. Indeed, transfer RNAs (tRNAs) are heavily modified with various different chemical structures added on nucleotides, thereby contributing to their stability and to translation accuracy ([@B1]). In eukaryotic and archaeal ribosomal RNAs (rRNAs), modifications such as pseudouridylation or 2′-*O*-methylation are introduced by RNA-guided multi-protein enzymes ([@B2]) while modifications on the bases such as methylation are introduced by protein-only enzymes ([@B3]). These rRNA modifications cluster mostly to functionally important regions of the ribosome (peptidyl transferase center, tRNA and mRNA binding sites, subunit-subunit interface) and hence contribute to its optimal activity ([@B4],[@B5]). More recently, the N6-methyladenosine (m^6^A) mRNA modification has been the focus of many studies aimed at clarifying the role of this epitranscriptomics modification on mRNA splicing, transport, translation and decay ([@B6]). Finally, translation factors are also subject to many post-translational events such as methylation. This is indeed the case for uS13, uL5 and eL42 ribosomal proteins (([@B10]); ribosomal proteins are numbered according to the naming proposed by Ban *et al.* ([@B11])) as well as translation elongation factors eEF1A, eEF2 and eEF3 (this later is only present in yeasts; ([@B12])). Bacterial (RF1 and RF2) and eukaryotic (eRF1) class I translation termination factors are also methylated on the glutamine side chain of the universally conserved GGQ motif that interacts with the peptidyl transferase center to trigger the release of the newly synthesized proteins ([@B18]). The methylation of the GGQ motif of the bacterial RF1 and RF2 proteins is catalyzed by PrmC. In eukaryotes, the same motif of eRF1 is modified by a complex formed by the Mtq2 methyltransferase (MTase) catalytic subunit and its activator Trm112 subunit ([@B19],[@B20],[@B24]). Interestingly, in *Saccharomyces cerevisiae*, the Trm112 protein also interacts with and activates three other MTases, namely Bud23, Trm9 and Trm11, which modify factors involved in translation ([@B28]). The Bud23--Trm112 complex and its human ortholog (BUD23-TRMT112 or WBSCR22-TRMT112) catalyze the N7-methylation of G nucleotide (m^7^G) at positions 1575 and 1639 on the yeast and human 18S rRNA, respectively, and these complexes are essential for 40S biogenesis ([@B29]). The Trm11--Trm112 complex catalyzes the addition of a methyl group on nucleotide G10 from several tRNAs to form N2-methylguanosine (m^2^G) thereby most likely contributing to their stability ([@B36],[@B37]). The Trm9--Trm112 complex and its human ortholog ALKBH8-TRMT112 are involved in the 5-methoxycarbonylmethyluridine (mcm^5^U) modification of the wobble position from the anticodon loop of some tRNAs and hence enhance translational fidelity and efficiency ([@B38]). It is noteworthy that human TRMT112 partners have been associated with diseases and are potential targets for drug developments. Indeed, ALKBH8 protein is highly expressed in a variety of human cancer cells including bladder cancer. Furthermore, ALKBH8 silencing induces apoptosis of urothelial carcinoma cells thereby suppressing tumor growth, angiogenesis and metastasis and also renders the cells sensitive to methyl methane sulfonate (MMS) and to the anti-cancer drug bleomycin ([@B41],[@B48]). Human BUD23 could be a tumor marker for invasive breast cancer, myeloma cells and hepatocarcinoma ([@B49]) and could contribute to lung pathologies ([@B52]).

Bioinformatics analyses have revealed the presence of Trm112 orthologues in bacteria and archaea suggesting that its role might extend outside eukaryotic organisms ([@B25],[@B28],[@B36]). While nothing is known on bacterial Trm112 orthologues, the detection of Mtq2, Trm9 and Trm11 orthologues in archaeal genomes together with the strong similarity between eukaryotic and archaeal translation machineries suggest that archaeal Trm112 might play a role similar to the eukaryotic Trm112 ([@B53]). Indeed, Trm11 orthologues (hereafter named aTrm11) from *Pyrococcus abyssii* and *Thermococcus kodakarensis* have been biochemically characterized as enzymes methylating guanine nucleotide at position 10 of some tRNAs ([@B56],[@B57]). However, these two enzymes not only catalyze the formation of N2-methylguanosine but also of N2,2-dimethylguanosine and do not require Trm112 to be active. Regarding Trm9, several observations argue in favor of its presence in some archaea. First, an initial survey of *Haloferax volcanii* genome suggested that the *HVO_0574* gene encodes for a potential Trm9 orthologue ([@B58]) but a more recent analysis proposed *HVO_1032* gene as a better candidate ([@B59]). Second, genes encoding for proteins displaying some sequence similarity with the various enzymes (Elp3, Tuc1 and Trm9) involved in the formation of mcm^5^s^2^U modification at position 34 of tRNAs are present in *H. volcanii* and genes for Elp3 and Trm9 orthologues cluster in *Sulfolobus solfataricus* ([@B58]). Third, studies in the early 90's revealed the presence of unknown modifications at position U~34~ of some tRNAs from *H. volcanii* ([@B60]). Regarding class I release factors, it is striking that despite radically different 3D-structures of the bacterial and eukaryotic factors, dedicated machineries have evolved to methylate the glutamine side chain of the universally conserved GGQ motif. Hence, one can imagine that such modification also exists on archaeal aRF1. Considering the structural similarity between aRF1 and eukaryotic eRF1 factor ([@B61],[@B62]), the enzyme responsible for this modification is very likely to be orthologous to Mtq2. This is further supported by the presence of an Mtq2 ortholog in all archaeal phyla ([@B25],[@B28]). Finally, so far, no m^7^G modification of the nucleotide corresponding to *S. cerevisiae* G~1575~ in archaeal 16S rRNA has been found, in agreement with the absence of proteins with significant sequence homology with Bud23 in archaeal genomes ([@B28]).

To clarify the roles of archaeal Trm112, we identified potential partners of Trm112 in the *H. volcanii* model organism by co-immunoprecipitation followed by mass spectrometry-based proteomic identification. We validated some of these partners, characterized the *in vivo* and *in vitro* biochemical functions of two of these and solved the crystal structure of another one. Altogether, our results show that *H. volcanii* Trm112 (hereafter named *Hvo*Trm112) displays striking similarities with its eukaryotic orthologs but is also able to interact with a much larger number of MTases than the eukaryotic Trm112.

MATERIALS AND METHODS {#SEC2}
=====================

Deletion of TRM112 and TRM9 genes in *H. volcanii* {#SEC2-1}
--------------------------------------------------

The chromosomal copy of the *HVO_1131* gene (hereafter named *HVO_TRM112*) encoding for *Hvo*Trm112 protein was deleted by the pop-in/pop-out method to generate the *Haloferax volcanii* H98 *trm112*Δ strain (*Hvo*MG5; [Supplementary Table S1](#sup1){ref-type="supplementary-material"}) using published protocols ([@B63],[@B64]). First, two 400 bp fragments covering the upstream (US) and downstream (DS) regions of the *HVO_TRM112* gene were amplified from *H. volcanii* genome by PCR using oligonucleotides oMG86/oMG87 and oMG88/oMG89, respectively ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). The PCR products were then digested with BamHI/XbaI and XhoI/BamHI restriction enzymes, respectively and then cloned into XbaI/XhoI digested plasmid pTA131 to obtain pTA131 containing US-DS of *HVO_TRM112* (pMG613) used for the pop-in/pop-out procedure.

Colonies resulting from excision of the plasmid (pop-out) were screened by colony lift to check for insertion of the Flag-tag sequence. A DIG-labelled PCR product using oligonucleotides oMG320 and oMG321 on genomic DNA was used as a probe, and detected using the DIG Luminescent Detection kit (Roche) and a ChemiDoc MP (BioRad). 52% of the colonies proved to be deleted for *HVO_TRM112* gene ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}).

An additional screening was performed by PCR on some colonies using oMG163 and oMG164 oligonucleotides ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}) to amplify the whole upstream and downstream parts of *HVO_TRM112* gene ([Supplementary Figure S1B](#sup1){ref-type="supplementary-material"}). Parts of colonies were picked and lysed by mixing in 50 μl water, and then used as DNA templates for PCR reaction. The PCR was performed with Q5 High-Fidelity DNA Polymerase (Biolabs), according to manufacturer\'s instruction (PCR conditions: one 30 s cycle at 98°C followed by 30 cycles (10 s at 98°C; 20 s at 62°C and 30 s at 72°C) and a final step of 2 min at 72°C).

To study the enzymatic activity of *Hvo*Trm9--Trm112 complex, an *H. volcanii* H26 strain deleted for the *HVO_1032* gene (*Hvo*MG2; [Supplementary Table S1](#sup1){ref-type="supplementary-material"}), which encodes for the putative Trm9 orthologue, was generated by the pop-in/pop-out method. First, two 400 bp fragments of upstream (US) and downstream (DS) regions surrounding *HVO_1032* gene in *H. volcanii* genome were amplified by PCR using oligonucleotides oMG72/oMG73 and oMG74/oMG75, respectively ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). The PCR products were then digested with BamHI/XbaI and XhoI/BamHI restriction enzymes, respectively and then cloned into XbaI/XhoI digested plasmid pTA131 to obtain pTA131 harboring US-DS of *HVO_1032* (pMG612). This plasmid was then used for pop-in/pop-out to delete *HVO_1032* gene as described above for the generation of the *H. volcanii* H98 *trm112*Δ strain. PCR were performed on genomic DNA from different colonies using oMG73 and oMG162 ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}) and revealed that 50% of the colonies were deleted for *HVO_1032* gene ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}).

Co-immunoprecipitation of *Hvo*Trm112-Flag protein {#SEC2-2}
--------------------------------------------------

To identify *Hvo*Trm112 protein partners, we expressed a Trm112-Flag protein from a plasmid and performed co-immunoprecipitation (co-IP) under cross-linking conditions as described below. First, the *HVO_TRM112* gene was amplified from *H. volcanii* genomic DNA using oligonucleotides oMG320/oMG321 (this later includes a sequence encoding for a Flag-tag; [Supplementary Table S2](#sup1){ref-type="supplementary-material"}). The PCR product was digested by NdeI and NotI restriction enzymes and later inserted into pTA962 digested with the same enzymes to yield pMG772. The pMG772 or pMG807 (pTA927-derived plasmid expressing only the Flag-tag as a control; generous gift from Prof. Anita Marchfelder, Ulm University, Germany) plasmids purified from competent *dam^−^ E. coli* cells were transformed into *Hvo*MG5 strain according to the pop-in procedure described above. The transformants were plated on YPC and incubated at 45°C for at least 5 days. This resulted in the *H. volcanii* H98 *trm112*Δ *Hvo*Trm112-Flag and *trm112*Δ Flag-only strains.

Next, one colony of *H. volcanii* strain H98 *trm112*Δ *Hvo*Trm112-Flag was used to over-express *Hvo*Trm112-Flag. First, the colonies were inoculated to 10 mL YPC (supplemented with thymidine 60 μg/mL), incubated O/N at 45°C and 150 rpm. In the next day, 2.5 ml O/N culture was applied to 1 L YPC (+thymidine 60 μg/ml) and grown O/N at 45°C and 150 rpm. On the third day, 18% SW-dissolved tryptophan was added to the O/N culture to the final concentration of 5 mM, followed by 6 h incubation at 45°C and 150 rpm for protein over-expression. The cells were harvested by centrifugation at 4000 rpm for 30 min. For the Flag-only control, the same protocol was used for *Hvo* H98 *trm112*Δ Flag-only strain.

Co-IP experiments of *Hvo*Trm112-Flag and of Flag-only were carried out as described in Fischer *et al.* ([@B65]), with some slight modifications (see supplementary materials for details). Proteomic analysis details are given in the supplementary materials.

In vitro studies of *Hvo*Trm112-MTase complexes {#SEC2-3}
-----------------------------------------------

The procedures for cloning, expression and purification of proteins and protein complexes used for *in vitro* studies (enzymology, SEC-MALLS and X-ray crystallography) are described in [supplementary materials](#sup1){ref-type="supplementary-material"}. The tRNAs from *S. cerevisiae* or *H. volcanii* strains were purified as previously described ([@B47]).

The MTase assays were performed in a total volume of 10 μl (for *Hvo*Mtq2-Trm112) or 20 μl (for *Hvo*Trm9--Trm112) containing 400 mM potassium phosphate buffer pH 7.5, 3 M KCl, 2.5 mM EDTA, 5 mM MgCl~2~, 5 mM NH~4~Cl, 0.25 mg/ml Bovine Serum Albumin, 50 μM *S*-adenosyl-[l]{.smallcaps}-methionine (SAM; containing 0.87 Ci/mmol of \[^3^H\]-SAM; Perkin Elmer) and 5 pmol of *Hvo*Mtq2--Trm112 complex or 2 pmol of *Hvo*Trm9--Trm112 complex. The reaction was initiated by adding 100 pmol of substrate (*Hvo*aRF1, *Hvo*aRF3 or total tRNAs) to the mixture. After incubation for 2 h at 45°C, the reaction was stopped by precipitation with cold trichloroacetic acid (5%), followed by filtration on Whatman GF/C filters. The \[^3^H\] incorporation was measured using a Beckman Coulter LS6500 scintillation counter.

Crystallization and structure determination of the *Hvo*\_0019--Trm112 complex {#SEC2-4}
------------------------------------------------------------------------------

Crystals of the *Hvo\_*0019--Trm112 complex were obtained by mixing 1 μL of protein complex (15 mg/ml in buffer B: 1 M NaCl, 20 mM Tris--HCl pH 7.5, 5 mM β-mercaptoethanol, 10 μM ZnCl~2~) with an equal volume of crystallization solution (0.1--0.3 M NaCl; 0.1 M Bis--Tris pH 5.5; 20--25% w/v PEG3350) at both 4°C and 24°C. Crystals appeared within 4--5 h and reached their maximum size (400 μm length) within 3 days. Crystals were cryo-protected by transfer into their crystallization condition supplemented with progressively higher glycerol concentration up to 30% and then flash-frozen in liquid nitrogen.

All datasets were collected on beam-line Proxima-2A (Synchrotron SOLEIL, Saint-Aubin, France) at 100 K. The structure was solved by Sulfur-SAD (Single Anomalous Dispersion) using a highly redundant dataset (seven datasets of 1400° each collected on different regions of a single crystal) collected at 2.0664 Å to get strong anomalous signal from sulfur atoms (see [Supplementary Table S3](#sup1){ref-type="supplementary-material"} for statistics). A 1.35 Å resolution dataset was obtained by merging two datasets collected at different crystal-detector distances on another crystal ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Data were processed with XDS ([@B66]) and scaled using XSCALE. All crystals belonged to space group *P*2~1~2~1~2~1~ with two copies of *Hvo\_*0019--Trm112 complex per asymmetric unit. Twenty-four sulfur sites (eleven per *Hvo\_*0019--Trm112 complex and two from *S*-adenosyl-[l]{.smallcaps}-homocysteine (SAH) molecules bound to *Hvo\_*0019 methyltransferase) were successfully located using SHELXD ([@B67]). Experimental phasing followed by density modification were performed with the PHASER_EP and RESOLVE programs implemented in the PHENIX suite ([@B68]). The final model was obtained by iterative cycles of building and refinement performed using COOT ([@B72]) and BUSTER ([@B73]) programs, respectively ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). The final model for *Hvo\_*0019--Trm112 complex contains *Hvo\_*0019 residues 2--227 (including the first histidine from the His~6~-tag) and 2--12, 15--231 (including five histidine residues from the His~6~-tag) for protomers A and B, respectively as well as *Hvo*Trm112 residues 1--59 and 1--25, 29--58 for protomers C and D, respectively. In addition, 387 water molecules, two SAH molecules and two glycerol molecules from the cryoprotectant solution have also been modeled. The coordinates and structure factors files are available from the Protein Data Bank (PDB) under accession code 6F5Z.

RESULTS {#SEC3}
=======

Identification of several partners of *Hvo*Trm112 protein by co-immunoprecipitation and proteomics {#SEC3-1}
--------------------------------------------------------------------------------------------------

*Hvo*Trm112 protein partners were isolated by co-immunoprecipitation (co-IP) of Flag-tagged *Hvo*Trm112 (Figure [1A](#F1){ref-type="fig"}). For this purpose, we deleted the *TRM112* gene in the *H. volcanii* H98 background by the pop-in/pop-out method as described in the methods section. Among all colonies, 52% lacked this gene indicating that *TRM112* is not an essential gene ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"} and B). The deletion of this gene did not affect generation time but resulted in much smaller colonies ([Supplementary Figure S1C and D](#sup1){ref-type="supplementary-material"}). The *H. volcanii trm112Δ* strain was then transformed with a plasmid encoding a C-terminally Flag-tagged version of *Hvo*Trm112 under the control of tryptophan inducible promoter. The *trm112Δ* strain was also transformed with a plasmid expressing only the Flag-tag (kind gift from Prof. Anita Marchfelder, Ulm University, Germany) as negative control. Before cell lysis, an *in vivo* cross-linking step was performed in the co-IP protocol by adding 1% formaldehyde as described by Fischer and colleagues ([@B65]). This step was added for the following reasons. First, an initial co-IP experiment with no cross-linking resulted in a low number of specific peptide spectra in the mass spectrometry analysis (data not shown). Second, *Hvo*Trm112 could interact with some of its partners in a transient manner. Third, protein--protein interactions in this organism might be maintained by high salt concentration while the low salt concentration used during the co-IP protocol could induce complex dissociation and/or result in protein aggregation (Figure [1A](#F1){ref-type="fig"}). Proteins co-immunoprecipitated with *Hvo*Trm112-Flag or with the Flag-tag control were identified by mass spectrometry as described in the [Supplemental methods](#sup1){ref-type="supplementary-material"}. This revealed that the cross-linking step resulted in an increased number of proteins identified by mass spectrometry coupled to a higher number of specific peptide MS/MS spectra.

![Trm112 interaction network in *H. volcanii*. (**A**) Schematic representation of the protocol used for co-immunoprecipitation of *Hvo*Trm112-Flag (purple shape) under cross-linking conditions. *H. volcanii* proteins are depicted as colored and filled geometric shapes. Cross-links are depicted by cyan lines. (**B**) SDS-PAGE analysis of the different purification steps. MW corresponds to molecular weight marker, T to Total extract,W to Washing fraction, E1 and E2 to Elution fractions. The bands corresponding to *Hvo*Trm112-Flag in the E1 and E2 fraction are highlighted by a black dashed box. The table analyses the molecular function gene ontologies of the 10 proteins exhibiting the higher NSAF values (excluding *Hvo*Trm112). (**C**) Enrichment of major 'molecular function' GO terms in the 100 proteins exhibiting the higher NSAF values in the *Hvo*Trm112-Flag co-IP experiments. Fold enrichment was calculated as the ratio between the percentage of proteins from a given 'molecular function' GO terms in the list of 100 proteins exhibiting the higher NSAF values and the percentage of proteins from the same 'molecular function' GO terms in the entire *H. volcanii* proteome. The dashed line shows an enrichment of one fold. Methyltransferase 'molecular function' GO term is shown in grey and was not included in the transferase 'molecular function' GO term in this analysis.](gky638fig1){#F1}

As suggested by the SDS-PAGE analysis of the co-IP results (Figure [1B](#F1){ref-type="fig"} and [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}), \>1000 proteins were identified by the LC--MS/MS analyses of four independent co-immunoprecipitation experiments of *Hvo*Trm112-Flag whereas only a few hundreds were identified in the negative control experiments with the Flag-only construct ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}). To reduce this extensive list, a series of stringent MS-based criteria (see supplemental information) were applied to select the most confident protein candidates. In addition, proteins already identified by Fischer *et al.* ([@B65]) in their co-immunoprecipitation of *Hvo*Lsm-Flag (performed in identical conditions to those used in our study) were considered as non-specific interacting partners (most probably, highly abundant proteins) and were removed. Those strict filtering criteria led to a final list of 499 proteins ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}).

We then ranked these proteins based on their Normalized Spectral Abundance Factor (NSAF; ([@B74])) and observed that *Hvo*Trm112 exhibited the higher NSAF value in agreement with its role as bait protein (Table [1](#tbl1){ref-type="table"}). Next, the analysis of the molecular functions (as defined by Gene Ontology terms) of the 100 proteins with the highest NSAF values in the *Hvo*Trm112-Flag co-IP experiments highlighted two molecular functions, i.e. translation/ribosome and methyltransferase (MTase), as strongly enriched among the potential Trm112 partners (Figure [1B](#F1){ref-type="fig"}--[C](#F1){ref-type="fig"}). Proteins endowed with 'ligase' molecular function are also enriched, although to a lesser extent, and more than half of these ligases (16 out of 29) are involved in protein synthesis process (i.e. amino-acyl tRNA synthetases or enzymes involved in amino acid metabolism). This fits with the function of the eukaryotic ortholog Trm112 as an activator of MTases modifying factors involved in translation (rRNAs, tRNAs, release factors). Further analysis revealed that 23 MTases out of the 62 predicted in the *H. volcanii* proteome are present in the list of 499 proteins (Table [1](#tbl1){ref-type="table"}). Seventeen of those are members of the class I MTase family and include homologs to known eukaryotic Trm112 MTase partners : Mtq2 (PrmC or *Hvo*\_2744, hereafter termed *Hvo*Mtq2), Trm9 (*Hvo*\_1032, named *Hvo*Trm9; ([@B59])) but also Trm11 (TrmG10/*Hvo*Trm11). Five are of the class III family ([@B75]) and one is not a SAM-dependent enzyme (MetE1). Hence, the *Hvo*Trm112 interaction network shares common features with the eukaryotic Trm112 interactome but might be more complex.

###### 

Trm112 and methyltransferases detected in the *Hvo*Trm112-Flag co-immunoprecipitation experiments

  Rank^a^   Symbol         UniProt accession number   NSAF         Putative function                                              Validated interaction with *Hvo*Trm112?   Predicted SAM-dependent MTase class
  --------- -------------- -------------------------- ------------ -------------------------------------------------------------- ----------------------------------------- -------------------------------------
  1         Trm112         D4GW82                     0.0598       Methyltransferase activator                                    \-                                        \-
  2         **HVO_0773**   **D4GTS8**                 **0.0193**   **Unknown**                                                    **[YES]{.ul}**                            **Class I**
  6         **TrmG10**     **D4GZA0**                 **0.0088**   **tRNA (Guanine(10).N(2))-dimethyltransferase**                **[NO]{.ul}^b^**                          **Class I**
  7         HVO_A0501      D4GRG4                     0.0084       Unknown                                                        Not tested                                Class I
  8         MenG           D4GZT8                     0.0084       Demethylmenaquinone methyltransferase                          Not tested                                Class I
  9         SirC           D4GWE7                     0.0083       Uroporphyrin-III C-methyltransferase                           Not tested                                Class III
  17        **HVO_0475**   **D4GS15**                 **0.0064**   **Unknown**                                                    **[YES]{.ul}**                            **Class I**
  18        HVO_1475       D4GYB0                     0.0064       DNA methylase                                                  Not tested                                Class I
  33        CbiT           D4GP64                     0.0051       cobalt-precorrin-6B C(15)-methyltransferase                    Not tested                                Class I
  38        CbiH2          D4GP59                     0.0045       Precorrin-3B C17-methyltransferase                             Not tested                                Class III
  41        *HVO_1032*     D4GVK8                     0.0044       tRNA (Uracil(34)) methyltransferase                            [YES]{.ul}                                Class I
  42        **HVO_0574**   **D4GSG9**                 **0.0043**   **Unknown**                                                    **[YES]{.ul}**                            **Class I**
  59        **HVO_2875**   **D4GXJ1**                 **0.0037**   **Unknown**                                                    **[YES]{.ul}**                            **Class I**
  64        **HVO_0019**   **D4GYL4**                 **0.0035**   **24-sterol C-methyltransferase**                              **[YES]{.ul}**                            **Class I**
  132       AglP           D4GYG5                     0.0023       Hexuronic acid methyltransferase                               Not tested                                Class I
  140       **PrmC**       **D4GW96**                 **0.0021**   **Class I translation termination factor methyltransferase**   **[YES]{.ul}**                            **Class I**
  149       CbiH1          D4GP60                     0.0019       Precorrin-3B C17-methyltransferase                             Not tested                                Class III
  211       CbiF           D4GP62                     0.0015       Cobalamin biosynthesis precorrin-3 methylase                   Not tested                                Class III
  240       HVO_1534       D4GYH8                     0.0014       Unknown                                                        Not tested                                Class I
  260       **HVO_1715**   **D4H060**                 **0.0013**   **Unknown**                                                    **[YES]{.ul}**                            **Class I**
  273       MetE1          D4GW90                     0.0012       Methionine synthase                                            Not tested                                SAM-independent MTase
  289       HVO_1093       D4GW13                     0.0011       Protein-L-isoaspartate O-methyltransferase                     Not tested                                Class I
  310       Dph5           D4GUZ5                     0.0010       Diphtine synthase                                              Not tested                                Class III
  341       HVO_2664       D4GV35                     0.0009       Unknown                                                        Not tested                                Class I

^a^Proteins were ranked from the highest to the lowest NSAF values.

^b^The interaction between these two proteins was not confirmed as *Hvo*Trm11 could not be expressed as a soluble protein in *E. coli* in the absence or the presence of *Hvo*Trm112.

Validation of several *Hvo*Trm112-MTase complexes {#SEC3-2}
-------------------------------------------------

To validate the co-IP and proteomic results, a subset of the identified SAM-dependent class I MTases was selected to test whether they are indeed *bona fide* binding partners of *Hvo*Trm112. In addition to the *H. volcanii* homologs of the known eukaryotic Trm112 partners, namely *Hvo*Mtq2, *Hvo*Trm9 and *Hvo*Trm11, six other MTases were chosen: *Hvo*\_0773 (exhibiting the highest NSAF value among the detected MTases), *Hvo*\_0475, *Hvo*\_0574 (initially proposed to be the Trm9 archaeal orthologue ([@B58])), *Hvo*\_2875, *Hvo*\_0019 and *Hvo*\_1715 (Table [1](#tbl1){ref-type="table"}). N-terminal His~6~-tagged versions of these MTases were expressed in *E. coli* either alone or with untagged *Hvo*Trm112 and purified on Ni-NTA resin as described in [Supplementary Materials and Methods section](#sup1){ref-type="supplementary-material"}. Interestingly, similarly to *S. cerevisiae* Mtq2, Trm9 and Bud23 ([@B25],[@B30],[@B42]), most MTases tested (*Hvo*Mtq2, *Hvo*Trm9, *Hvo*\_0019, *Hvo*\_1715, *Hvo*\_0773 and *Hvo*\_2875) can only be over-expressed as soluble proteins in the presence of *Hvo*Trm112 ([Supplementary Figure S4A](#sup1){ref-type="supplementary-material"}). Only two (*Hvo*\_0475 and *Hvo*\_0574) do not require *Hvo*Trm112 for efficient soluble expression ([Supplementary Figure S4B](#sup1){ref-type="supplementary-material"}). Next, we performed a 3-steps (Ni-NTA, ion-exchange and size-exclusion chromatographies) purification protocol from *E. coli* cultures co-expressing each His-tagged MTase with *Hvo*Trm112. In all cases but *Hvo*Trm11 (see below), at the end of this stringent purification protocol, we could observe a second major band, migrating at the expected size for *Hvo*Trm112 in addition to the band corresponding to the tagged MTase. Mass spectrometry analyses confirmed that for each MTase tested, these bands correspond to both the MTase of interest and to *Hvo*Trm112 (data not shown). This demonstrates that *Hvo*Trm112 interacts individually with almost all the tested MTases and that the resulting complexes are stable. SEC-MALLS analyses further revealed that these *Hvo*Trm112-MTase complexes adopt different oligomeric states (Table [2](#tbl2){ref-type="table"}; [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}), *i.e*. heterodimers (*Hvo*Trm9--Trm112, *Hvo*Mtq2--Trm112, *Hvo*\_0773--Trm112, *Hvo*\_0574--Trm112 and *Hvo*\_1715-Trm112), heterotetramers (*Hvo*\_0019--Trm112) or heterohexamers (*Hvo*\_0475-Trm112). Despite extensive efforts (optimized gene, fusion with GST, different *E. coli* expression strains or temperature), it was not possible to express *Hvo*Trm11 as a soluble protein, neither alone nor in the presence of *Hvo*Trm112 ([Supplementary Figure S4C](#sup1){ref-type="supplementary-material"}). Hence, we cannot conclude about the direct interaction between *Hvo*Trm11 and *Hvo*Trm112.

###### 

Oligomeric states of *Hvo*Trm112-MTase complexes

  Trm112-MTase complex   Theoretical MW of heterodimer (kDa)   Experimental MW determined by SEC-MALLS (kDa)   Oligomeric states
  ---------------------- ------------------------------------- ----------------------------------------------- -------------------
  *Hvo*Trm9--Trm112      31                                    29.5                                            Heterodimer
  *Hvo*Mtq2-Trm112       28.9                                  27.3                                            Heterodimer
  *Hvo*\_0019--Trm112    33.2                                  59.8                                            Heterotetramer
  *Hvo*\_0574-Trm112     36.8                                  34.6                                            Heterodimer
  *Hvo*\_0475-Trm112     40.1                                  117                                             Heterohexamer
  *Hvo*\_0773-Trm112     35.4                                  33.9                                            Heterodimer
  *Hvo*\_1715-Trm112     34.6                                  32.3                                            Heterodimer
  Hvo_2875-Trm112 ^a^    28.6                                  ND                                              ND

^a^Due to low yields, SEC-MALLS analysis could not be performed on this complex.

ND: Not determined.

We thus conclude that in *H. volcanii*, Trm112 interacts directly with at least eight different MTases (*Hvo*Mtq2, *Hvo*Trm9, *Hvo*\_0019, *Hvo*\_0773, *Hvo*\_0574, *Hvo*\_0475, *Hvo*\_2875 and *Hvo*\_1715). Its interaction network is then much more complex than for its eukaryotic orthologs studied so far ([@B28]).

Characterization of *Hvo*Mtq2--Trm112 and *Hvo*Trm9--Trm112 enzymatic activities {#SEC3-3}
--------------------------------------------------------------------------------

Among all these *Hvo*Trm112 partners, there are clear orthologues for two eukaryotic Trm112 partners, namely Mtq2 and Trm9, paving the way towards their functional characterization.

In eukaryotes, the Mtq2-Trm112 complex is enzymatically active on class I translation termination factor eRF1 but only when this later exists as a complex with the GTP-bound form of class II translation termination factor eRF3 ([@B25],[@B26]). To characterize the enzymatic activity of the recombinant *Hvo*Mtq2-Trm112 complex *in vitro*, we over-expressed in *E. coli* and purified both *Hvo*aRF1 and *Hvo*aRF3 (also known as *Hvo*aEF1A). First, the *Hvo*aRF1 methylation activity of the *Hvo*Mtq2-Trm112 complex, in the presence of *Hvo*aRF3 and GTP, was measured both in the absence and presence of KCl (3M), the latter corresponding to physiological conditions ([@B76]). In agreement with several reports on *H. volcanii* enzymes, a strong methylation activity was detected only in the presence of KCl (Figure [2A](#F2){ref-type="fig"}). In these conditions, *Hvo*Mtq2-Trm112 complex catalyzes the methylation of nearly 26 pmol of *Hvo*aRF1 out of 100 pmol in 2 h. To rule out the possibility that the detected enzymatic activity resulted from an *E. coli* contaminant, we substituted Tyr111 from the NPPY signature in *Hvo*Mtq2 by Ala with the aim of inactivating the *Hvo*Mtq2-Trm112 complex as the corresponding *S. cerevisiae* Mtq2 mutant is completely inactive ([@B27]). No enzymatic activity could indeed be detected for this Y111A *Hvo*Mtq2--Trm112 mutant (Figure [2A](#F2){ref-type="fig"}). In addition, substitution of Gln187 in the *Hvo*aRF1 GGQ motif to Ala also resulted in undetectable activity. Finally, both *Hvo*aRF3 and GTP were necessary for methylation of *Hvo*aRF1 by the *Hvo*Mtq2--Trm112 complex.

![The *Hvo*Mtq2-Trm112 complex modifies the GGQ motif of *Hvo*aRF1 protein. (**A**) *In vitro* enzymatic activity of *Hvo*Mtq2--Trm112 complex. The conditions (proteins, salt and ligand) used for each experiment are indicated in the table below each graph. The amount of methylated substrate (in pmol) after a 2 h reaction is indicated for every condition. Error bars have been calculated from the results of three independent experiments. (**B**) Mass spectrometry analysis of the methylation status of the GGQ motif of *Hvo*aRF1 proteins purified from different *H. volcanii* strains or methylated *in vitro*. (**C**) MS/MS spectrum of the ^185^GG**Q**SAQRFA^193^ methylated peptide from *Hvo*aRF1 protein purified from *trm112Δ* strain. The methylated glutamine is highlighted in bold. (**D**) MS/MS spectrum of the ^173^SASSLVPGKQRKGG**Q**^187^ peptide from *Hvo*aRF1 protein purified from *E. coli* and not incubated with *Hvo*Mtq2-Trm112 complex. The glutamine of interest is highlighted in bold.](gky638fig2){#F2}

Next, we investigated the *in vivo* methylation state of the *Hvo*aRF1 GGQ motif in different *H. volcanii* strains. First, we deleted *HvoMTQ2* gene in *H. volcanii* and observed that this deletion severely affects the generation time (251 minutes compared to 128 minutes for wild-type; [Supplementary Figure S1C](#sup1){ref-type="supplementary-material"}) and results in small size colonies (similarly to *trm112Δ* strains). Hence, as previously described in *S. cerevisiae* ([@B20],[@B42]), the *MTQ2* gene is also important for optimal growth in *H. volcanii*. Second, we introduced a Flag-tag at the C-terminal extremity of the *Hvo*aRF1 protein in the three following strains: WT, *mtq2Δ* and *trm112Δ* and purified *Hvo*aRF1-Flag from these three strains. Using mass spectrometry, we analyzed for the presence of a methyl group on the GGQ motif of these endogenous *Hvo*aRF1 proteins. We could detect the presence of a methyl group on the glutamine residue of the GGQ motif on the *Hvo*aRF1 protein purified from WT and *trm112Δ* strains but not from the *mtq2Δ* strain (Figure [2B](#F2){ref-type="fig"}, C and [Supplementary Figure S6](#sup1){ref-type="supplementary-material"}). As control, we expressed *Hvo*aRF1 in *E. coli*, purified it and incubated it with the *Hvo*Mtq2-Trm112 holoenzyme under optimal conditions for *in vitro* enzymatic activity. Mass spectrometry analyses revealed the presence of methylated glutamine only on *Hvo*aRF1 protein incubated with the *Hvo*Mtq2--Trm112 holoenzyme (Figure [2B](#F2){ref-type="fig"} and [Supplementary Figure S6](#sup1){ref-type="supplementary-material"}).

Altogether, this demonstrates that *Hvo*Mtq2--Trm112 holoenzyme catalyzes the methylation of the glutamine side chain from the *Hvo*aRF1 GGQ motif in an *Hvo*aRF3- and GTP-dependent manner similarly to its yeast and human orthologs ([@B25],[@B26]). This also reveals that in *H. volcanii*, Mtq2 is mandatory for *Hvo*aRF1 methylation *in vivo* while Trm112 is not, explaining the strong differences in generation times between the *trm112Δ* and *mtq2Δ* strains (251 ± 13 min versus 123 ± 6 min, respectively; [Supplementary Figure S1C](#sup1){ref-type="supplementary-material"}).

In parallel, we investigated whether the *Hvo*Trm9--Trm112 acts as a tRNA modification enzyme similarly to its eukaryotic ortholog. To obtain putative tRNA substrates, we generated an *H. volcanii* H26 strain deleted for the *HVO_1032* gene (hereafter termed *H. volcanii trm9Δ*), which encodes for *Hvo*Trm9, by the pop-in/pop-out method as described above for the *H. volcanii trm112Δ* strain construction. 50% of the colonies obtained after plasmid excision (pop-out) were deleted for *HvoTRM9* gene (3 out of 6 tested, [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). Our ability to obtain this deletion mutant indicates that the gene encoding for *Hvo*Trm9 is not essential. Contrary to the deletion of *H. volcanii TRM112* gene, the deletion of *HvoTRM9* gene did not affect the size of the colonies but resulted in an affected generation time (178 min compared to 128 min for wild-type *H. volcanii* strain; [Supplementary Figure S1C, D](#sup1){ref-type="supplementary-material"}). Total tRNAs purified from this strain as well as those purified from *S. cerevisiae trm9Δ* or *elp1Δ* strains ([@B47]) were used for *in vitro* enzymatic assays. Surprisingly, the *Hvo*Trm9--Trm112 complex was active on total tRNAs from *S. cerevisiae trm9Δ* strain as substrates but not from *H. volcanii trm9Δ* strain (Figure [3A](#F3){ref-type="fig"}). *Hvo*Trm9--Trm112 complex (2 pmol) modifies up to 5.5 pmol of tRNAs from *S. cerevisiae trm9Δ* strain out of 100 pmol while *S. cerevisiae* Trm112-Trm9 complex (1.5 pmol) was modifying up to 7 pmol (out of 75 pmol) of the same tRNAs ([@B47]). As observed for *Hvo*Mtq2--Trm112 complex, *Hvo*Trm9--Trm112 complex is significantly more active in the presence of 3 M KCl than in the absence of KCl, where only ∼1.5 pmol of tRNAs are modified. Its activity depends on the presence of the cm^5^U (5-carboxymethyluridine) modification at position 34 of tRNA anticodon loop as tRNAs purified from *S. cerevisiae elp1Δ* strain are not substrates of this complex. Finally, as *Hvo*\_0574 gene product, which also interacts with *Hvo*Trm112, was initially predicted to be orthologous to eukaryotic Trm9 ([@B58]), we have included this purified complex in our enzymatic assays. As shown in Figure [3A](#F3){ref-type="fig"}, this complex does not exhibit enzymatic activity on total tRNAs extracted from either *S. cerevisiae trm9Δ* or *H. volcanii trm9Δ* strains.

![The *Hvo*Trm9--Trm112 complex catalyzes the formation of mcm^5^U on tRNAs. (**A**) *In vitro* enzymatic activity of *Hvo*Trm9--Trm112 complex. The conditions (proteins, salt and tRNAs) used for each experiment are indicated in the table below each graph. The amount of methylated substrate (in pmol) after a 2 h reaction is indicated for every condition. Error bars have been calculated from the results of three independent experiments. (**B**) Reversed phase LC--MS/MS elution profiles measured from 50 pmol of synthesized mcm^5^U standard or a 2 μg injection of a total tRNA digest from WT, *trm9Δ* or *trm112Δ* strains. (**C**) Reversed phase LC--MS/MS elution profiles measured from 50 pmol of synthesized cm^5^U standard or a 2 μg injection of a total tRNA digest from WT, *trm9Δ* or *trm112Δ* strains. (**D**) SRM product ions ([Supplementary Table S9](#sup1){ref-type="supplementary-material"}) measured for the cm^5^U standard (top) and for the unknown molecule eluted 1 minute later than cm^5^U in the digested WT tRNAs sample (bottom).](gky638fig3){#F3}

Next, we have tried to clarify our surprising observation that tRNAs extracted from the *H. volcanii trm9Δ* strain are not substrates of the *Hvo*Trm9--Trm112 complex and to document the chemical nature of the yet uncharacterized modifications found at U~34~ on several *H. volcanii* tRNAs (tRNA^Arg(UCG)^, tRNA^Glu(UUC)^, tRNA^Gly(UCC)^, tRNA^Lys(UUU)^, tRNA^Leu(UAG)^; ([@B60],[@B77])). We then performed nucleoside analyses following total digestion of tRNAs extracted from *H. volcanii* WT, *trm9Δ* or *trm112Δ* strains by reversed phase LC--MS/MS. This revealed that the mcm^5^U (5-methoxycarbonylmethyluridine) nucleoside exists only in tRNAs from WT but neither from *trm9Δ* nor *trm112Δ* strains (Figure [3B](#F3){ref-type="fig"}). In parallel, the assay showed no presence of cm^5^U in the tRNAs extracted from all these strains at the retention time of the standard (Figure [3C](#F3){ref-type="fig"}). Interestingly, a second peak was detected in the assay having the same transition as cm^5^U yet eluting a minute later. We found the later eluting peak to have a different ion ratio to that of the cm^5^U standard indicating this was not cm^5^U (Figure [3C](#F3){ref-type="fig"}--[D](#F3){ref-type="fig"}). To further verify the absence of cm^5^U in the original sample, a 500 ng spike of cm^5^U standard was added to the WT strain and subjected to analysis ([Supplementary Figure S7](#sup1){ref-type="supplementary-material"}). This showed the presence of the cm^5^U spike as well as the later eluting peak with their respective ion ratio. While the later eluting peak has not been identified in this work, it is clear that all samples lacked the cm^5^U modification. To our knowledge, these results demonstrate for the first time that the mcm^5^U modification exists in *H. volcanii* and most probably in other archaea with a Trm9 ortholog. They also show that both *Hvo*Trm9 and *Hvo*Trm112 proteins are necessary for the formation of mcm^5^U *in vivo*. Finally, these analyses rationalize the lack of enzymatic activity of the *Hvo*Trm9--Trm112 complex on tRNAs purified from the *trm9Δ H. volcanii* strain due to the absence of the cm^5^U Trm9 substrate in those tRNAs. This strongly indicates that in the absence of *Hvo*Trm9 or *Hvo*Trm112, cm^5^U is rapidly converted into other chemical structures (such as for instance, ncm^5^U as previously observed in *Δtrm9 S. cerevisiae* strain ([@B44])) that remain to be identified. Altogether, these results demonstrate that the *Hvo*Trm9--Trm112 complex is indeed a tRNA methyltransferase, which, similarly to its eukaryotic ortholog, modifies cm^5^U into mcm^5^U (5-methoxycarbonylmethyluridine) at position 34 of the tRNAs as the cm^5^U modification, catalyzed by the Elp1-6 complex in eukaryotes ([@B78],[@B79]), is required for enzymatic activity.

Structure of a Trm112--MTase complex from *H. volcanii* {#SEC3-4}
-------------------------------------------------------

To gain insight into the molecular bases responsible for the interaction between *Hvo*Trm112 and its interacting MTase partners, different *Hvo*Trm112-MTase complexes were subjected to crystallization trials in the presence or in the absence of SAM. Crystals diffracting up to 1.35Å resolution were obtained for the *Hvo*\_0019--Trm112 complex. The structure of this complex was solved at 2.5Å resolution by the Sulfur-SAD method ([Supplementary Figure S8](#sup1){ref-type="supplementary-material"}) by taking advantage of the high number of sulfur atoms in this complex (11, excluding the initial methionine from *Hvo*\_0019, which is very likely to be excised in *E. coli* ([@B80])). The structure was further refined at high resolution using a 1.35Å resolution native dataset to yield a final model with *R* and *R*~free~ values of 18.5% and 20.7%, respectively. There are two virtually identical copies of the *Hvo*\_0019--Trm112 complex in the asymmetric unit (Figure [4A](#F4){ref-type="fig"}; rmsd value of 0.27 Å over 211 Cα atoms). Each complex is bound to a SAH molecule, most probably co-purified with *Hvo*\_0019--Trm112 complex.

![Crystal structure of *Hvo*\_0019--Trm112 complex. (**A**) Ribbon representation of the heterotetrameric *Hvo*\_0019--Trm112 complex. The SAH molecule bound to each *Hvo*\_0019 monomer is shown as yellow sticks. (**B**) Ribbon representation of the *Hvo*\_0019--Trm112 heterodimer. (**C**) Sequence conservation mapped at the surface of *Hvo*\_0019 protein structure. Only the heterodimer is shown for the sake of clarity. Conservation scores have been calculated from an alignment of 241 sequences using the Consurf server ([@B91]). The SAM methyl group modeled by superimposing the structure of *S. cerevisiae* Bud23 ([@B33]) onto the structure of *Hvo*\_0019 is shown as a yellow sphere. Opaque regions correspond to the interior of the proteins. (**D**) Comparison of *Hvo*\_0019 (blue) and NodS (grey) active sites with conserved residues shown as sticks. Labels for NodS residues are underlined and in italics. SAH is shown as yellow sticks.](gky638fig4){#F4}

Structurally, *Hvo*\_0019 adopts the typical class-I SAM-dependent MTase fold composed of a central seven stranded β-sheet surrounded by three α-helices (the C-terminal half of αZ, αA and αB) on one side and two on the other side (αD, αE; Figure [4B](#F4){ref-type="fig"}). On top of the central β-sheet, four α-helices (αY, the N-terminal half of αZ, α1 and α2) contribute to the formation of a cavity centered on the sulfur atom from the SAH molecule bound to the *Hvo*\_0019 protein. SAH binds in a canonical manner compared to what was observed for other class I SAM-dependent MTases. *Hvo*Trm112 structure consists of only the zinc knuckle domain previously observed in eukaryotic Trm112 proteins (rmsd values of 1.1--1.4 Å over around 55 Cα atoms; ([@B25],[@B27],[@B33],[@B47])), including a small N-terminal α-helix (α1) and a four-stranded anti-parallel β-sheet (Figure [4B](#F4){ref-type="fig"}). Contrary to eukaryotic Trm112 proteins and some structurally similar bacterial proteins (PDB code: 2KPI) of known structures, there is no zinc atom bound to *Hvo*Trm112 in agreement with the absence of conservation of the cysteine residues involved in zinc coordination. The interface between *Hvo*Trm112 and *Hvo*\_0019 has an overall area of 975 Å^2^ and is slightly smaller than the previously described interfaces between eukaryotic Trm112 and its MTase partners ([@B33],[@B47]). This most likely results from the absence of the helical domain, specific to eukaryotic Trm112 proteins, that was in part contributing to these interactions. Complex formation involves 20 and 21 residues from *Hvo*Trm112 and *Hvo*\_0019, respectively ([Supplementary Figure S9](#sup1){ref-type="supplementary-material"}). The core of this interface is formed by hydrophobic residues (M1, L5, I8, L9, P12, I50, P51, L53, L54, P55 and M58 from *Hvo*Trm112 and F66, F89, L90, V91, L97, P98 and F99 from *Hvo*\_0019; [Supplementary Figure S9](#sup1){ref-type="supplementary-material"}). Such a large hydrophobic interface rationalizes the strong solubilization effect that we observe for *Hvo*Trm112 upon co-expression with *Hvo*\_0019 in *E. coli* ([Supplementary Figure S4A](#sup1){ref-type="supplementary-material"}). This hydrophobic core is surrounded by polar residues (K2, D7, C10, K15, E29, N52 and R59 from *Hvo*Trm112 and S2, R64, Q76, R79, D85, D86, S88, D93, D96, D100, S103, E125 and R128 from *Hvo*\_0019). Six hydrogen bonds and three salt bridges are also observed at the interface ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}). Two hydrogen bonds formed between main chain atoms of V91 from *Hvo*\_0019 with P51 as well as L53 from *Hvo*Trm112, are responsible for the formation of a β-zipper interaction between *Hvo*Trm112 strand β4 and *Hvo*\_0019 strand β3 (Figure [4B](#F4){ref-type="fig"}). Other hydrogen bonds are formed between P98, L97, R64 and D100 from *Hvo*\_0019 and C10, K15, S4 and I8 from *Hvo*Trm112, respectively. Finally, salt bridges are formed by K15 from *Hvo*Trm112 with D96 and E125 from *Hvo*\_0019, and by D7 from *Hvo*Trm112 with R64 from *Hvo*\_0019.

As stated above, there are two copies of *Hvo*\_0019--Trm112 complex in the asymmetric unit and these are related by a two-fold symmetry axis (Figure [4A](#F4){ref-type="fig"}). These copies interact together through a large surface area of 840 Å^2^. As SEC-MALLS measurements on this complex have revealed that it forms heterotetramer in solution ([Supplementary Figure S5](#sup1){ref-type="supplementary-material"}; Table [2](#tbl2){ref-type="table"}), this contact area most likely corresponds to the biological interface responsible for this oligomeric state. This homodimerization interface is exclusively formed by residues from *Hvo*\_0019, more precisely from strands β6 and β7 and helix αZ. Hence, the MTase partner seems to govern the formation of oligomeric states, explaining why depending on the MTase, *Hvo*Trm112-MTase complexes are either heterodimers, heterotetramers or heterohexamers in solution (Table [2](#tbl2){ref-type="table"}).

BLAST searches for proteins sharing sequence similarity with *Hvo*\_0019 identified orthologous proteins mostly from specific archaeal phyla such as halobacteriales and thaumarchaeota but also from some bacteria (*Legionella shakespearei, Agrobacterium tumefaciens, rhodobacteriaceae, flavobacteriaceae, acidobacteria*). Multiple sequence alignments revealed the presence of few highly conserved residues ([Supplementary Figure S9B](#sup1){ref-type="supplementary-material"}). Interestingly, in *Hvo*\_0019 structure, these residues cluster around the expected position of the SAM methyl group and form a strongly conserved pocket, which is very likely to correspond to the enzyme active site (Figure [4C](#F4){ref-type="fig"}). Comparison of *Hvo*\_0019 protein structure with previously described structures of MTases revealed a significant degree of conservation with the active site of NodS MTase from *Bradyrhizobium japonicum* ([@B81]). NodS is involved in the biosynthesis of the Nod factor, a modified chitosaccharide acting as a signal molecule in rhizobia. It is catalyzing the methylation of the NH~2~ group of Nod glucosamine moiety. Indeed, residues R22, E111, Y114, Y115 and W152 from *Hvo*\_0019 structurally match with R21, E115, Y118, Y119 and W156 from NodS, respectively (Figure [4D](#F4){ref-type="fig"}). In addition, the side chains from *Hvo*\_0019 W10 and NodS W20 are also in close vicinity. Altogether, this suggests that *Hvo*\_0019 might modify a substrate with a hexose sugar ring. Further studies will be needed to characterize the enzymatic activity of the *Hvo*\_0019--Trm112 complex.

DISCUSSION {#SEC4}
==========

Protein translation is one of the most intricate processes in cell biology and requires numerous factors acting in a highly coordinated choreography. Most of these translational factors (tRNAs, rRNAs and proteins) are frequently subjected to post-transcriptional and post-translational modifications to perform correct functions. Methylation is so far known as the most prevalent modification of translation machinery. In yeast, effects of methylation on translation are perfectly illustrated by Trm112, an obligate activator for at least four methyltransferases contributing to ribosome biogenesis and function. The importance of this interacting network is also reflected by its conservation in human where these MTases are associated with diseases ([@B28]). Sequence analyses revealed that Trm112 orthologues are also found in archaea and bacteria. As most of the translational machinery components are very similar between eukaryotes and archaea, this raised the question of the existence of a similar Trm112 interacting network in archaea.

One protein, many MTase partners {#SEC4-1}
--------------------------------

In *S. cerevisiae* and human, Trm112/TRMT112 is known to directly interact with at least four class I SAM-dependent MTases, namely Bud23/BUD23, Trm9/ALKBH8, Trm11/TRMT11 and Mtq2/HEMK2 ([@B28]). Here, using co-immunoprecipitation of Flag-tagged Trm112 from *H. volcanii* under cross-linking conditions, we have observed a significant enrichment of MTases as potential Trm112 partners (Figure [1](#F1){ref-type="fig"} and Table [1](#tbl1){ref-type="table"}), *i.e*. about 36% of all the MTases predicted by bioinformatics analysis of *H. volcanii* genome. From this list, we selected nine class I SAM-dependent MTases for further validation and could demonstrate that at least eight interact directly with *Hvo*Trm112 ([Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). Hence, *H. volcanii*, and probably more generally archaeal, Trm112 interaction network is larger than anticipated from our current knowledge in eukaryotes, and we cannot exclude that additional MTase partners listed in Table [1](#tbl1){ref-type="table"} await for experimental validation. Our experimental approach proved very powerful as only three potential partners could have been identified by bioinformatics analyses based on their similarity with eukaryotic Mtq2, Trm9 and Trm11 proteins (no Bud23 ortholog could be found in *H. volcanii* and in archaea in general; ([@B28],[@B59])). These three MTases are found as potential *Hvo*Trm112 partners in our co-IP experiments but we could validate their interaction with *Hvo*Trm112 only for *Hvo*Trm9 and *Hvo*Mtq2 as we were unable to over-express *Hvo*Trm11 in a soluble form in *E. coli*. The presence of *Hvo*Trm11 in the list of putative partners was somehow surprising as the orthologous proteins from two archaea (*P. abyssii* and *T. kodakarensis*) were previously shown to be sufficient to catalyze the mono- and di-methylation of G~10~ on some tRNAs *in vitro* ([@B56],[@B57]). This could be explained by our recent analysis of the distribution of Trm112 orthologues within archaeal genomes. Indeed, Trm112 is absent in thermococcales and methanobacteriales, which include *Pyrococcus abyssii* and *Thermococcus kodakarensis* ([@B28]). Hence, we propose that when present in an archaeal organism, aTrm112 interacts directly with aTrm11 while when absent, aTrm11 has evolved to be active on its own. Studies aimed at clarifying this aspect are in progress.

The identification of at least six additional MTases able to directly interact with *Hvo*Trm112, which is only composed of 61 amino acids, was completely unexpected. Bioinformatics analyses revealed that among those, three (*Hvo*\_0773, *Hvo*\_0475 and *Hvo*\_0574) might be specific for halobacteriales phylum from euryarcheota, which includes *H. volcanii*. The three remaining MTases (*Hvo*\_0019, *Hvo*\_1715 and *Hvo*\_2875) are found in some specific archaeal phyla such as halobacteriales (*Hvo*\_0019, *Hvo*\_1715 and *Hvo*\_2875), thaumarchaeota (*Hvo*\_0019) and thermococcales (*Hvo*\_2875) but also in some bacteria. For instance, *Hvo*\_0019 orthologues could be identified in *Legionella shakespearei, Agrobacterium tumefaciens* and *Limnothrix rosea* ([Supplementary Figure S9B](#sup1){ref-type="supplementary-material"}). Similarly, proteins sharing significant sequence identity with *Hvo*\_1715 are present in Bacilli (such as *Bacillus anthracis* and *Streptococcus pneumoniae*) and in mycobacteria. This is also the case for *Hvo*\_2875 present in nocardia. This suggests that in bacteria, Trm112 orthologues could also interact with MTases. This is further supported by several observations. First, the structures of bacterial Trm112 orthologues (PDB codes: 2KPI and 2JS4) are highly similar to the zinc-knuckle domains from *H. volcanii* and eukaryotic Trm112 proteins (rmsd of 1.4 to 1.8 Å). Second, superimposition of these bacterial structures onto those of Trm112-MTase complexes reveals that the Trm112 region involved in the interaction with MTases adopts the same structure in bacterial proteins and hence is compatible with MTase binding ([@B28]). Third, in some bacteria, genes encoding for Trm112 and MTases are fused and this is often an indication of physical interaction. Finally, a recent study aimed at identifying protein-protein interactions in *Desulfovibrio vulgaris* detected that Trm112 orthologue (DVU0656) interacts with three MTases (HemK, UbiE and Sun), some of which could also have a role in translation ([@B82]).

Structural studies of eukaryotic Trm112-MTase complexes have shown that all these MTases interact in a very similar way with Trm112 and hence directly compete ([@B27],[@B33],[@B37],[@B47]). The crystal structure of the *Hvo*\_0019--Trm112 complex solved here reveals striking similarities between archaea and eukaryotes. Indeed, *Hvo*\_0019--Trm112 and eukaryotic Trm112-MTase complexes superimpose almost perfectly (Figure [5A](#F5){ref-type="fig"}; rmsd values ranging from 1.7 Å to 2.15 Å between the different heterodimers). A first hallmark common to all these complexes is the presence of a parallel β-zipper interaction formed between Trm112 strand β4 and MTase strand β3 (Figure [5A](#F5){ref-type="fig"}). The formation of this β-zipper relies on hydrogen bonds between amino acid main chain atoms from both partners and hence is less affected by substitutions of amino acid located in the MTase strand β4. This very likely explains that Trm112 proteins can have many partners adopting the same overall fold. A second conserved feature between eukaryotic and archaeal Trm112-MTase complexes is the presence of a hydrophobic core at the complex interface, which most likely rationalizes the solubilizing and stabilizing effects observed for Trm112 on several MTases ([Supplementary Figure S4A](#sup1){ref-type="supplementary-material"}; ([@B25],[@B30],[@B42])). We propose that as in eukaryotes, all identified *Hvo*MTases compete and interact in a very similar mode with *Hvo*Trm112. This is further supported by the fact that all these archaeal MTases are SAM-dependent class I MTases and hence adopt the same overall three-dimensional structure. In addition, the comparison of *Hvo*\_0019 residues directly contacting *Hvo*Trm112 with the structurally equivalent residues in all other *Hvo*Trm112 MTase partners identified here, highlights a significant degree of conservation (Figure [5B](#F5){ref-type="fig"}). Indeed, positions forming the hydrophobic core at the interface between *Hvo*\_0019 and *Hvo*Trm112 are largely occupied by hydrophobic residues in the other *Hvo*Trm112 MTase partners.

![A conserved interaction mode between eukaryotic and archaeal Trm112-MTase complexes. (**A**) Superimposition of the crystal structures of *Hvo*\_0019--Trm112 and *S. cerevisiae* Bud23--Trm112 complexes. Strands forming the β-zipper interaction between Trm112 and the MTases are labeled. The zinc atom bound to *Sc*Trm112 is shown as a black sphere. The SAH molecule bound to *Hvo*\_0019 MTase is shown as gray sticks. (**B**) Sequence alignment of all *Hvo*MTases that have been experimentally confirmed to be direct partners of *Hvo*Trm112. For the sake of clarity, only the region of the MTase domain contacting *Hvo*Trm112 is shown. Secondary structure elements assigned from the *Hvo*\_0019 crystal structure are indicated above the alignment. Black closed circles indicate *Hvo*\_0019 positions involved in interaction with *Hvo*Trm112. This figure was generated with the Espript server ([@B92]).](gky638fig5){#F5}

Then, similarly to what was described for eukaryotic Trm112 proteins, SAM-dependent class I MTases appear as privileged Trm112 partners in archaea. As some of these MTases are not strictly conserved within the archaeal domain of life, the number of MTase partners may vary between archaea. Finally, the similarities found for some of these archaeal proteins with bacterial MTases further suggest that Trm112 interacts with MTases in the three domains of life and that their interaction mode is conserved.

Functional characterization of translation-related complexes {#SEC4-2}
------------------------------------------------------------

Among the MTases validated as *Hvo*Trm112 partners, two (*Hvo*Mtq2 and *Hvo*Trm9) have convincing assigned functions based on their significant sequence similarity with eukaryotic proteins. We have experimentally demonstrated the biochemical functions of *Hvo*Mtq2--Trm112 and *Hvo*Trm9--Trm112 complexes both *in vitro* and *in vivo* based on our current knowledge of biochemical functions of eukaryotic Mtq2-Trm112 and Trm9--Trm112 complexes.

First, we have shown that the *Hvo*Mtq2-Trm112 complex exhibits an *in vitro* MTase activity on wild-type (but not on the GGA mutant of the universally conserved GGQ motif) class I release factor aRF1 only in the presence of 3M KCl, a common trend of *H. volcanii* enzymes (Figure [2A](#F2){ref-type="fig"}). As observed for yeast and human Trm112-Mtq2 complexes, this activity is dependent on the presence of the GTP-bound form of class II translation termination factor aRF3 ([@B25],[@B26]). This reflects the high similarity between eukaryotic and archaeal translation termination factors eRF1/aRF1 and eRF3/aRF3 ([@B62]). We also demonstrate that *Hvo*aRF1 is methylated on the glutamine side chain of its GGQ motif in *H. volcanii* cells and that this modification requires *Hvo*Mtq2 protein but not *Hvo*Trm112 (Figure [2B](#F2){ref-type="fig"} and [C](#F2){ref-type="fig"}). As *Hvo*Mtq2 orthologues are found in all archaea ([@B28]), we propose that the glutamine side chain of the universally conserved GGQ motif from aRF1 is methylated in archaea in general. The conservation of this post-translational modification in the three domains of life strongly argues in favor of an important biological role. Indeed, despite radically different structures of bacterial RF1/RF2 on one side and eRF1/aRF1 on the other side, these organisms have independently evolved enzymatic machineries to add a methyl group on the NH~2~ group of the glutamine side chain of their universally conserved GGQ motif ([@B24],[@B62],[@B83]). In bacteria, the methylation of RF1/RF2 GGQ motif by PrmC has been shown to be important for normal growth, to increase the affinity of RF1/RF2 for ribosomes and to enhance translation termination ([@B84],[@B85]). In eukaryotes and archaea, the role of this modification still remains to be clarified. However, the growth defect phenotype observed in *S. cerevisiae* and *H. volcanii* upon deletion of *MTQ2* gene ((20), this study) together with the conservation of this modification in eukaryotes and archaea argue in favor of a strong functional importance for this post-translational modification.

We have also reconstituted a tRNA MTase activity for *Hvo*Trm9--Trm112 complex *in vitro* but only using tRNAs purified from a *trm9Δ S. cerevisiae* strain as substrate. As observed for *Hvo*Mtq2-Trm112, this enzymatic activity is salt-dependent (Figure [3A](#F3){ref-type="fig"}). The strict requirement of the cm^5^U modification at position 34 of tRNAs indicates that *Hvo*Trm9--Trm112 complex catalyzes the formation of mcm^5^U~34~ similarly to eukaryotic Trm9--Trm112 complexes ([@B42],[@B44],[@B47]). This is further supported by the detection of the mcm^5^U nucleoside in tRNAs purified from WT but not from *trm9Δ* or *trm112Δ* strains (Figure [3B](#F3){ref-type="fig"}). To our knowledge, this is the first experimental evidence for the existence of the mcm^5^U modification in archaeal tRNAs. Surprisingly, tRNAs purified from a *Δtrm9 H. volcanii* strain were not substrates for the *Hvo*Trm9--Trm112 complex. Indeed, we did not detect the cm^5^U modification, the known substrate of the Trm9--Trm112 complex, in tRNAs from both *H. volcanii trm9Δ* or *trm112Δ* strains (Figure [3C](#F3){ref-type="fig"}--[D](#F3){ref-type="fig"}), indicating that this cm^5^U intermediate is unstable and rapidly converted into another modification, which could be ncm^5^U, similarly to what has been observed for some tRNAs in yeast ([@B44]). It is noteworthy that this modification, which biosynthetic pathway remains obscure, has been detected in tRNA^Leu(UAG)^ from *T. acidophilum* archaeon ([@B86]). Further studies will be needed to precisely characterize the chemical structures of the modifications found at position U~34~ from other *H. volcanii* tRNAs but also more generally in archaea. Due to the highly polar nature of modified uridines, which results in low ionization efficiency, this is very likely to be challenging. Hence, the similarity between archaeal *Hvo*Trm112 and its eukaryotic orthologues is not solely restricted to its ability to interact with class I dependent MTases but also extends to the *in vivo* and *in vitro* biochemical functions of at least two MTase partners (*Hvo*Trm9 and *Hvo*Mtq2) and most probably *Hvo*Trm11, which all modify components contributing to mRNA translation. Together with the strong enrichment of translation factors or ribosome components in our co-IP experiments, this supports an important role of archaeal Trm112 in translation and strengthens the analogies between eukaryotic and archaeal translation apparatus.

CONCLUSION {#SEC5}
==========

Trm112 proteins, which are found in the three domains of life, have been characterized exclusively in eukaryotes so far, where these are partners and activators of several MTases modifying factors of the protein synthesis machinery. Here, we have characterized Trm112 network in archaea using *Haloferax volcanii* as model organism. In this organism, Trm112 interacts with at least eight different MTases. Some exhibit similar functions as their eukaryotic orthologues, further supporting the similarities between eukaryotic and archaeal translation machineries. Other MTases are orthologous to bacterial proteins, strongly suggesting that bacterial Trm112 proteins might also interact with MTases, in agreement with a recent study ([@B82]).

Members of Trm112 family are not unique in their ability to interact with several MTases. Indeed, it has been shown that Vea protein from *Aspergillus nidulans* acts as a hub protein interacting with at least four MTases, some of which being involved in development, secondary metabolism and fungal pathogenicity ([@B87],[@B88]). Hence, precise understanding of molecular details ruling the association of a single protein with various proteins adopting the same fold but exhibiting low sequence identity is of importance to decipher the numerous interaction networks that contribute to most cellular pathways ([@B89],[@B90]).
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